Article originally published in PLC Life Sciences Handbook 2012
M&A in the life sciences sector has remained robust, driven by factors such as:
- The need to replenish shrinking product pipelines.
- The need to maintain revenues as patents on top-selling
- products expire.
- The strategic diversification of business lines.
- Expansion into emerging markets.